Login / Signup

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.

Sandro PasqualiEmanuela PalmeriniVittorio QuagliuoloJavier Martin-BrotoAntonio Lopez-PousaGiovanni GrignaniAntonella BrunelloJean Yves BlayOscar TenderoRobert Diaz-BeveridgeVirginia FerraresiIwona LugowskaGabriele InfanteLuca BragliaDomenico Franco MerloValeria FontanaEmanuela MarchesiDavide Maria DonatiElena PalassiniGiuseppe BianchiAndrea MarrariCarlo MorosiSilvia StacchiottiSilvia BaguéJean Michel CoindreAngelo Paolo Dei TosPiero PicciPaolo BruzziRosalba MiceliPaolo Giovanni CasaliAlessandro Gronchi
Published in: Cancer (2021)
People affected by soft tissue sarcomas of the extremities and trunk wall are at some risk of developing metastasis after surgery. Preoperative or postoperative chemotherapy has been tested in clinical trials to reduce the chances of distant metastasis. However, study findings have not been conclusive. This study stratified the risk of metastasis for people affected by sarcomas who were included in a clinical trial testing neoadjuvant chemotherapy. Exploiting the prognostic nomogram Sarculator, it found a benefit for chemotherapy when the predicted risk, based on patient and tumor characteristics, was high.
Keyphrases
  • neoadjuvant chemotherapy
  • locally advanced
  • clinical trial
  • soft tissue
  • lymph node
  • sentinel lymph node
  • rectal cancer
  • patients undergoing
  • squamous cell carcinoma
  • radiation therapy
  • phase ii
  • open label